Developing a Multimodal miR-15a Mimic to Overcome Gemcitabine and RAS(ON) Inhibitor Daraxonrasib Resistance in Pancreatic Ductal Adenocarcinoma
Gemcitabine remains a mainstay of pancreatic ductal adenocarcinoma (PDAC) treatment, while the RAS(ON) inhibitor daraxonrasib has recently demonstrated imp